Banner_Prostate Cancer News

New cancer vaccine shows early promise in human clinical trials

Cancer patient looks at doctor for new cancer vaccine ideas

Studies from the 2018 American Urological Association meeting show that Testosterone Replacement Therapy (TRT) doesn't increase prostate cancer recurrence or progression during active surveillance. After a 47-month follow-up, recurrence rates post-surgery or radiation were low (11.6% and 4.1%, respectively), with a 10.6% progression rate during surveillance. This suggests TRT is safe for men with low testosterone and symptoms, but could influence treatment decisions during surveillance.

Read the full article by Renal and Urology News here.

decorative background image

Read More About Prostate Cancer

Enjoy our library of additional news articles, our Journey to ZERO blog, and our ZEROHour newsletter.

Share